ASCO 2015 | Results for the follow-up of the RESPONSE study
Jean-Jacques Kiladjian
Dr Jean-Jacques Kiladjian discusses the results of the follow up to the RESPONSE study of ruxolitinib versus standard therapy for the treatment of patients with polycythemia vera.
Related videos
2:38
MPN updates: personalized prognostication, novel treatments & more
Ruben Mesa
1:30
LCL161 for primary myelofibrosis: a new therapy in the field
Naveen Pemmaraju
6:57
Key updates in MPNs from ASH 2018
Claire Harrison
1:25
Highlights on myelofibrosis from ASH
Claire Harrison
3:07
Ruxolitinib plus azacitidine for myelofibrosis
Naval Daver
